In the news release, Decision Resources Publishes New Report on Novel Anticoagulants, issued yesterday, June 11, by Decision Resources, over PR Newswire, the first paragraph, second sentence, should read "growing from $1.5 billion in 2000 to $5.9 billion" rather than "growing from $1.5 million in 2000 to $5.9 million" as originally issued inadvertently. Complete, corrected release follows:
Decision Resources Publishes New Report on Novel Anticoagulants Report Forecasts That Sales of Anticoagulant Therapies Will More Than Triple Between 2001 and 2011
WALTHAM, Mass., June 11 /PRNewswire/ -- Decision Resources announced today the availability of a new report on the anticoagulant drug market. The report entitled Novel Anticoagulants forecasts that sales of anticoagulant therapies will more than triple between 2001 and 2011 in the major pharmaceutical markets (United States, the United Kingdom, Germany, France, Spain, Italy and Japan), growing from $1.5 billion in 2000 to $5.9 billion in 2011.
"The growth of the anticoagulant market will be lead by the introduction and uptake of AstraZeneca's Exanta prescribed for both atrial fibrillation and deep vein thrombosis/pulmonary embolism as well as Sanofi-Synthelabo/Organon's Arixtra for the treatment and preventative treatment of deep vein thrombosis/pulmonary embolism," said Nicola Maidwell, analyst, Decision Resources. "Other novel therapies that act directly on both previously targeted and untargeted clotting factors will contribute to the changes in the management of anticoagulation as well."
Novel Anticoagulants provides a thorough analysis of the epidemiology, a review of disease treatment and overview of current anticoagulant therapies in four of the major anticoagulant markets - atrial fibrillation, deep vein thrombosis/pulmonary embolism, acute ischemic stroke and unstable angina. The report focuses on the forecasts for novel specific compounds, novel drug classes and current therapies.
About Abnormal Blood Clotting
Abnormal blood clot formation, or thrombosis, can diminish or block the flow of blood and oxygen supply to critical blood vessels in vital organs, leading to serious clinical conditions. Complications that can arise from thrombosis include deep vein thrombosis/pulmonary embolism, acute ischemic stroke, and acute coronary syndromes (unstable angina, myocardial infarction).
Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Discorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states; Novel Anticoagulants is a Cardium report.
About Decision Resources
Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The Company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources 781-296-2563 firstname.lastname@example.org
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
Web site: http://www.dresources.com/